Literature DB >> 16217704

Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively.

J Klepper1, H Scheffer, B Leiendecker, E Gertsen, S Binder, M Leferink, C Hertzberg, A Näke, T Voit, M A Willemsen.   

Abstract

BACKGROUND: GLUT1 deficiency syndrome is caused by impaired glucose transport into the brain resulting in an epileptic encephalopathy, developmental delay, and a complex motor disorder. A ketogenic diet provides an alternative fuel to the brain and effectively restores brain energy metabolism.
METHODS: Fifteen children with GLUT1 deficiency syndrome were enrolled prospectively for a 2.0 - 5.5-year follow-up of the effectiveness of a 3 : 1 LCT ketogenic diet. Eight patients enrolled were described previously, seven patients were novel.
RESULTS: Four novel heterozygous GLUT1 mutations were identified. 10/15 patients remained seizure-free on the ketogenic diet in monotherapy. In 2/15 patients seizures recurred after 2(1/2) years despite adequate ketosis, but were controlled by add-on ethosuximide. In one patient seizures were reduced without complete seizure control. No serious adverse effects occurred and parental satisfaction with the diet was good. 2/15 patients discontinued the diet.
CONCLUSION: GLUT1 deficiency syndrome represents a complex childhood encephalopathy that can be treated effectively by means of a ketogenic diet. The response to the diet did not correlate to clinical, biochemical, or genetic features of the disease. In contrast to previous reports, our results indicate that epilepsy is not always completely controlled by a ketogenic diet and can recur in a subset of patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16217704     DOI: 10.1055/s-2005-872843

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  28 in total

Review 1.  Genetic Discoveries Drive Molecular Analyses and Targeted Therapeutic Options in the Epilepsies.

Authors:  Ryan S Dhindsa; David B Goldstein
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

Review 2.  Epileptic encephalopathies: new genes and new pathways.

Authors:  Sahar Esmaeeli Nieh; Elliott H Sherr
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 3.  Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: a systematic review of published prospective studies.

Authors:  Qian-Yun Cai; Zhong-Jie Zhou; Rong Luo; Jing Gan; Shi-Ping Li; De-Zhi Mu; Chao-Min Wan
Journal:  World J Pediatr       Date:  2017-07-12       Impact factor: 2.764

4.  Dietary Treatments and New Therapeutic Perspective in GLUT1 Deficiency Syndrome.

Authors:  Pierangelo Veggiotti; Valentina De Giorgis
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

Review 5.  The low-carbohydrate diet and cardiovascular risk factors: evidence from epidemiologic studies.

Authors:  T Hu; L A Bazzano
Journal:  Nutr Metab Cardiovasc Dis       Date:  2014-01-02       Impact factor: 4.222

6.  Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.

Authors:  Juan M Pascual; Peiying Liu; Deng Mao; Dorothy I Kelly; Ana Hernandez; Min Sheng; Levi B Good; Qian Ma; Isaac Marin-Valencia; Xuchen Zhang; Jason Y Park; Linda S Hynan; Peter Stavinoha; Charles R Roe; Hanzhang Lu
Journal:  JAMA Neurol       Date:  2014-10       Impact factor: 18.302

7.  Ketone Bodies as a Possible Adjuvant to Ketogenic Diet in PDHc Deficiency but Not in GLUT1 Deficiency.

Authors:  F Habarou; N Bahi-Buisson; E Lebigot; C Pontoizeau; M T Abi-Warde; A Brassier; K H Le Quan Sang; C Broissand; S Vuillaumier-Barrot; A Roubertie; A Boutron; C Ottolenghi; P de Lonlay
Journal:  JIMD Rep       Date:  2017-05-17

8.  Structural signatures and membrane helix 4 in GLUT1: inferences from human blood-brain glucose transport mutants.

Authors:  Juan M Pascual; Dong Wang; Ru Yang; Lei Shi; Hong Yang; Darryl C De Vivo
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

Review 9.  Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS).

Authors:  Toni S Pearson; Cigdem Akman; Veronica J Hinton; Kristin Engelstad; Darryl C De Vivo
Journal:  Curr Neurol Neurosci Rep       Date:  2013-04       Impact factor: 5.081

Review 10.  Ketone bodies as a therapeutic for Alzheimer's disease.

Authors:  Samuel T Henderson
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.